Search research articles
Contact Us
Filters
Showing results (91-100 of 100) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 100 results.
ACS Applied Materials & Interfaces
|
December 11, 2020
Aminated Fullerene Abrogates Cancer Cell Migration by Directly Targeting Myosin Heavy Chain 9
Wei Zhou, Jiawei Huo, Yang Yang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
September 12, 2025
A "3+2" Cooperation Pattern of Amphipathic AIE Phototheranostic System for Multimodal Image-Guided Synergistic Type I/II Photodynamic-Photothermal Therapy
Haijun Ma, Yibo An, Yuanyuan Han, et al.
Clinical Epidemiology
|
August 9, 2016
Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events
John Acquavella, Vera Ehrenstein, Morten Schiødt, et al.
ACS Nano
|
January 29, 2026
A "Jack-of-All-Trades" Phototheranostic System Enabled by Strategic Regulation of Ferroptosis and PANoptosis for Cancer Therapy
Xiaoli Lu, Lan Xie, Huan Yu, et al.
Cancer Medicine
|
February 29, 2020
Once-weekly (70 mg/m<sup>2</sup> ) vs twice-weekly (56 mg/m<sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials
Philippe Moreau, Keith A Stewart, Meletios Dimopoulos, et al.
Journal of the American Chemical Society
|
February 28, 2026
Stabilizing Radicals in Aggregation-Induced Emission Rotor-Polyoxometalate Crystals for Efficient Photothermal Conversion
Guokang He, Xinwen Ou, Cheng Liu, et al.
Nature Communications
|
January 8, 2026
METTL3 abrogation promotes glioma progression through regulating the ISG15-FASN axis-mediated lipid metabolism in macrophages
Huilong Yin, Xiaoyi Yu, Chenglong Hu, et al.
The Lancet. Oncology
|
May 12, 2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Ignace Vergote, Giovanni Scambia, David M O'Malley, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 100) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 100 results.
ACS Applied Materials & Interfaces
|
December 11, 2020
Aminated Fullerene Abrogates Cancer Cell Migration by Directly Targeting Myosin Heavy Chain 9
Wei Zhou, Jiawei Huo, Yang Yang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
September 12, 2025
A "3+2" Cooperation Pattern of Amphipathic AIE Phototheranostic System for Multimodal Image-Guided Synergistic Type I/II Photodynamic-Photothermal Therapy
Haijun Ma, Yibo An, Yuanyuan Han, et al.
Clinical Epidemiology
|
August 9, 2016
Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events
John Acquavella, Vera Ehrenstein, Morten Schiødt, et al.
ACS Nano
|
January 29, 2026
A "Jack-of-All-Trades" Phototheranostic System Enabled by Strategic Regulation of Ferroptosis and PANoptosis for Cancer Therapy
Xiaoli Lu, Lan Xie, Huan Yu, et al.
Cancer Medicine
|
February 29, 2020
Once-weekly (70 mg/m<sup>2</sup> ) vs twice-weekly (56 mg/m<sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials
Philippe Moreau, Keith A Stewart, Meletios Dimopoulos, et al.
Journal of the American Chemical Society
|
February 28, 2026
Stabilizing Radicals in Aggregation-Induced Emission Rotor-Polyoxometalate Crystals for Efficient Photothermal Conversion
Guokang He, Xinwen Ou, Cheng Liu, et al.
Nature Communications
|
January 8, 2026
METTL3 abrogation promotes glioma progression through regulating the ISG15-FASN axis-mediated lipid metabolism in macrophages
Huilong Yin, Xiaoyi Yu, Chenglong Hu, et al.
The Lancet. Oncology
|
May 12, 2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Ignace Vergote, Giovanni Scambia, David M O'Malley, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
Christian Marth, Ignace Vergote, Giovanni Scambia, et al.
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Page
of 10